Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 17/20 | 0.63 |
| ▸ | CDK12 | Q9NYV4 | 16/20 | 0.63 |
| ▸ | CDK2 | P24941 | 14/20 | 0.63 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.63 |
| ▸ | CCNT1 | O60563 | 12/20 | 0.63 |
| ▸ | CDK9 | P50750 | 12/20 | 0.63 |
| ▸ | CDK7 | P50613 | 9/20 | 0.50 |
| ▸ | CCNH | P51946 | 9/20 | 0.50 |
| ▸ | MNAT1 | P51948 | 7/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24588759 | 1.00 | CCNK (0.63) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL25597463 | 1.00 | CCNK (0.63) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL30203953 | 0.90 | CDK2 (0.49) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL21179237 | 0.89 | CCNK (0.53) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL21188444 | 0.88 | CCNK (0.54) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL24583204 | 0.88 | CCNK (0.52) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL29749443 | 0.87 | CCNK (0.53) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL24583163 | 0.87 | CCNK (0.53) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL21188533 | 0.87 | CDK2 (0.53) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL29083554 | 0.87 | CDK2 (0.53) | CCNKCDK12CDK2CCNE1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CCNK 11/4885CDK12 28/4885CDK2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.